Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600645's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Zhongyuan Union Cell & Gene Engineering was -19.50% per year. The lowest was -45.50% per year. And the median was -32.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Zhongyuan Union Cell & Gene Engineering Dividend Payout Ratio Related Terms
Zhongyuan Union Cell & Gene Engineering Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering Dividend Payout Ratio Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Dividend Payout Ratio falls into.
Zhongyuan Union Cell & Gene Engineering Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #999999 out of 133 companies in the Biotechnology industry.
Is Zhongyuan Union Cell & Gene Engineering's Dividend Payout Ratio too high?
Zhongyuan Union Cell & Gene Engineering's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #999999 out of 133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #999999 out of 133 companies for Dividend Payout Ratio. This places Zhongyuan Union Cell & Gene Engineering in the lower half of its industry. The industry median Dividend Payout Ratio is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 133 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.36, compared to a current price of ¥17.92 — trading 12% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥17.92 is trading 12% below its estimated GF Value™ of ¥20.36.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
Dividend Payout Ratio: 0.00
GF Value™: ¥20.36 vs. price of ¥17.92 (12% below fair value)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Business Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score
Get the complete analysis for SHSE:600645
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
